Mabion SA
WSE:MAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (3.3), the stock would be worth zł-9.85 (217% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.8 | zł8.41 |
0%
|
| 3-Year Average | 3.3 | zł-9.85 |
-217%
|
| 5-Year Average | 3.1 | zł-9.11 |
-208%
|
| Industry Average | 21.7 | zł-64.45 |
-866%
|
| Country Average | 8.6 | zł-25.4 |
-402%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
zł127.5m
|
/ |
Oct 2025
zł-46.8m
|
= |
|
|
zł127.5m
|
/ |
Dec 2025
zł-23.2m
|
= |
|
|
zł127.5m
|
/ |
Dec 2026
zł-29.7m
|
= |
|
|
zł127.5m
|
/ |
Dec 2027
zł-13.5m
|
= |
|
|
zł127.5m
|
/ |
Dec 2028
zł20.2m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
M
|
Mabion SA
WSE:MAB
|
135.9m PLN | -2.8 | -2.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 14.1 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 12.2 | 19.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 21.1 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41.2 | 38.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 10.4 | 30.4 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 5.4 |
| Median | 8.6 |
| 70th Percentile | 14.8 |
| Max | 1 215.6 |
Other Multiples
Mabion SA
Glance View
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
